Skip to content

PTGX

Protagonist Therapeutics, Inc.

Revenue to net income

Key figures

MetricLatest5-year CAGR
Revenue$552M+10.0%
Gross profit$273MQ3 2026—
Operating income$323M—
Net income$342M—
EPS$4.72—
Free cash flow$109M—